The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
Open accessAbstract
Antibodies blocking the programmed death 1 receptor (PD-1) on T cells produce tumor regression in multiple cancers by disrupting the PD-L1/ PD-1 (programmed death-ligand 1/programmed cell death protein 1) immune inhibitory axis.[1][2][3][4][5] This approach to cancer immunotherapy would seem to be an ideal partner for chimeric antigen receptor (CAR)modified T-cell therapies but is, as yet, untested in this setting.We report a case in which a PD-1 blocking antibody was administered to a patient with refractory diffuse large B-cell lymphoma (DLBCL) and progressive lymphoma after therapy with CAR-modified T cells directed against CD19 (CART19).Following PD-1 blockade, the patient had a clinically significant antitumor response, an expansion of CART19 cells, and decreased coexpression of PD-1 and Eomes by CART19 cells.This case suggests that PD-1 blockade can be effective against cancers failing to respond to CAR-modified T-cell therapy.It also suggests that the PD-1 pathway may be critical in determining the response to CAR-modified T-cell immunotherapy.A 35-year-old man with multiply pretreated, refractory DLBCL of primary mediastinal origin with extranodal involvement of small intestine at diagnosis, and mediastinum, lung, myocardium, and pericardium at progression was treated on a clinical trial at the University of Pennsylvania with autologous CART19 cells expressing murine anti-CD19 scFv and 4-1BB-CD3z costimulatory-activation domains (NCT02030834). 6 CART19 cells were manufactured as previously reported.7,8 He received lymphodepleting chemotherapy with hyperfractionated cyclophosphamide (300 mg/m 2 3 6 doses), followed by autologous CART19 cell infusion (5 3 10 8 CART19 cells or 5.34 3 10 6 cells/kg), day 0. Follow-up chest computed tomographic (CT) scan performed on day 26 to evaluate worsening dyspnea showed Day 45 Day 26
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Antibodiesblocking theprogrammeddeath1 receptor (PD-1) onTcells produce tumor regression in multiple cancers by disrupting the PD-L1/ PD-1 (programmed death-ligand 1/programmed cell death protein 1) immune inhibitory axis.(1-5) This approach to cancer immunotherapy would seem to be an ideal partner for chimeric antige…”
BackgroundNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Antibodiesblocking theprogrammeddeath1 receptor (PD-1) onTcells produce tumor regression in multiple cancers by disrupting the PD-L1/ PD-1 (programmed death-ligand 1/programmed cell death protein 1) immune inhibitory axis.(1-5) This approach to cancer immunotherapy would seem to be an ideal partner for chimeric antige…”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Self-citationJohn, L. B., Devaud, C., Duong, C. P. M., Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H., & Darcy, P. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0458 · Cited by 694
Schuster, S. J., Svoboda, J., Nasta, S. D., Porter, D., Chong, E. A., Landsburg, D. J., Mato, A. R., Lacey, S. F., Melenhorst, J. J., Chew, A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.183.183 · Cited by 79
Self-citation
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
McLane, L. M., Abdel-Hakeem, M. S., & Wherry, E. J. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055318 · Cited by 1,975
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Self-citationClinical implications of T cell exhaustion for cancer immunotherapy
Chow, A., Perica, K., Klebanoff, C. A., & Wolchok, J. D. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00689-z · Cited by 1,044
Metadata
- Authors
- Chong, E. A., Melenhorst, J. J., Lacey, S. F., Ambrose, D. E., Gonzalez, V., Levine, B. L., June, C. H., & Schuster, S. J.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-02-23
- Volume
- 129
- Issue
- 8
- Pages
- 1039-1041
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2566018578
- Cited by
- 496
- References
- 9
- FWCI
- 21.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. https://app.cochat.ai/papers/10.1182/blood-2016-09-738245
- The paper
- Chong, E. A., Melenhorst, J. J., Lacey, S. F., Ambrose, D. E., Gonzalez, V., Levine, B. L., June, C. H., & Schuster, S. J. (2017). PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. https://doi.org/10.1182/blood-2016-09-738245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.